Skip to main content

Advertisement

Table 5 Follow-up of 7 patients with AML-M2/M3 until 30th june, 2012

From: Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes

  Chemotherapy treatment Subsequent Time*(days, d) Final diagnosis
  In our deparmett Treatment
Case 1 3 cycles allo-SCT** 1630d CR
Case 2 4 cycles auto-SCT 1492d CR
Case 3 1 cycle - 3d Death
Case 4 5 cycles allo-SCT 766d CR
Case 5 1 cycle - >29d Non-remission, lost at follow-up
Case 6 4 cycles - 467d Recurrence, transformed into AMLM2
Case 7 1 cycle - 53d CR
  1. allo-SCT, allogeneic stem cell transplantation; auto-SCT: autologous stem cell transplantation.
  2. *closing date: 30 June, 2012.
  3. **the patient had the allo-SCT in another hospital.